AUTOLOGOUS STEM CELL-BASED GENE THERAPY OFFERS AN INNOVATIVE SOLUTION FOR TREATING INHERITED BLOOD CELLS DISORDERS
Downloads
Recent advancements in medical treatments, particularly gene therapy using hematopoietic stem cells (HSCs), have significantly impacted the treatment of inherited blood disorders. HSCs can self-renew and differentiate into blood cells, making them essential for treating conditions like sickle cell anemia, thalassemia, and severe combined immunodeficiency (SCID). This study conducted a literature review on autologous stem cell therapy for genetic blood disorders, analyzing studies from databases such as PubMed and Scopus. Gene therapy corrects genetic defects in HSCs, offering an alternative to allogeneic transplantation by avoiding immune rejection. The therapy involves modifying stem cells in the lab, often through viral vectors or gene-editing tools, and reinfusing them into the patient to produce healthy blood cells long-term. Lentiviral vectors, considered safer than retroviruses, have been particularly effective in treating various conditions, including immunodeficiencies and hemoglobinopathies. The ex vivo gene transfer approach, commonly used for genetic disorders, has shown promise for one-time curative treatments, especially for pediatric diseases. However, early gene therapy efforts, such as the use of gamma-retroviral vectors for SCID, faced complications like leukemia, leading to a shift towards safer lentiviral vectors. Despite its complexity, the procedure has a low failure rate and provides a less risky alternative to traditional allogeneic stem cell transplants. Ultimately, HSC gene therapy holds significant potential for curing genetic blood disorders by permanently altering the stem cells, ensuring long-term benefits and improved treatment outcomes, with ongoing advancements in safety and efficacy.
Aiuti, A., Biasco, L., Scaramuzza, S., Ferrua, F., Cicalese, M. P., Baricordi, C., Dionisio, F., Calabria, A., Giannelli, S., Castiello, M. C., Bosticardo, M., Evangelio, C., Assanelli, A., Casiraghi, M., di Nunzio, S., Callegaro, L., Benati, C., Rizzardi, P., Pellin, D., di Serio, C., Schmidt, M., von Kalle, C., Gardner, J., Mehta, N., Meduva, V., Dow, D. J., Galy, A., Miniero, R., Finocchi, A., Metin, A., Banerjee, P. P., Orange, J. S., Galimberti, S., Valsecchi, M. G., Biffi, A., Montini, E., Villa, A., Ciceri, F., Roncarolo, M. G. and Naldini, L. (2013), “Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome”, Science, Vol. 341 No. 6148.
Aiuti, A., Slavin, S., Aker, M., Ficara, F., Deola, S., Mortellaro, A., Morecki, S., Andolfi, G., Tabucchi, A., Carlucci, F., Marinello, E., Cattaneo, F., Vai, S., Servida, P., Miniero, R., Roncarolo, M. G. and Bordignon, C. (2002), “Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning”, Vol. 296 No. 5577, pp. 2410-3.
Bach, F. H., Albertini, R. J., Joo, P., Anderson, J. L. and Bortin, M. M. (1968), “Bone-marrow transplantation in a patient with the Wiskott-Aldrich syndrome”, Lancet, Vol. 2 No. 7583, pp. 1364-6.
Cavazzana, M., Bushman, F. D., Miccio, A., André-Schmutz, I. and Six, E. (2019), “Gene therapy targeting haematopoietic stem cells for inherited diseases: progress and challenges”, Nature Reviews Drug Discovery, Vol. 18 No. 6, pp. 447-62.
Cavazzana-Calvo, M., Hacein-Bey, S., de Saint Basile, G., Gross, F., Yvon, E., Nusbaum, P., Selz, F., Hue, C., Certain, S., Casanova, J. L., Bousso, P., Deist, F. L. and Fischer, A. (2000), “Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease”, Science, Vol. 288 No. 5466, pp. 669-72.
Dunbar, C. E., High, K. A., Joung, J. K., Kohn, D. B., Ozawa, K. and Sadelain, M. (2018), “Gene therapy comes of age”, Science, Vol. 359 No. 6372.
Gatti, R. A., Meuwissen, H. J., Allen, H. D., Hong, R. and Good, R. A. (1968), “Immunological reconstitution of sex-linked lymphopenic immunological deficiency”, Lancet, Vol. 2 No. 7583, pp. 1366-9.
Giommetti, A. and Papanikolaou, E. (2024), “Advancements in Hematopoietic Stem Cell Gene Therapy: A Journey of Progress for Viral Transduction”, Cells, Vol. 13 No. 12, pp. 1039.
Hacein-Bey-Abina, S., Kalle, C. V., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., Sorensen, R., Forster, A., Fraser, P., Cohen, J. I., de Saint Basile, G., Alexander, I., Wintergerst, U., Frebourg, T., Aurias, A., Stoppa-Lyonnet, D., Romana, S., Radford-Weiss, I., Gross, F., Valensi, F., Delabesse, E., Macintyre, E., Sigaux, F., Soulier, J., Leiva, L. E., Wissler, M., Prinz, C., Rabbitts, T. H., Deist, T. L., Fischer, A. and Cavazzana-Calvo, M. (2003), “LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1”, Science, Vol. 302 No. 5644, pp. 415-9.
Hatzimichael, E. and Tuthill, M. (2010), “Hematopoietic stem cell transplantation”, Stem Cells and Cloning, Vol. 3, pp. 105-17.
Howe, S. J., Mansour, M. R., Schwarzwaelder, K., Bartholomae, C., Hubank, M., Kempski, H., Brugman, M. H., Pike-Overzet, K., Chatters, S. J., de Ridder, D., Gilmour, K. C., Adams, S., Thornhill, S. I., Parsley, K. L., Staal, F. J. T., Gale, R. E., Linch, D. C., Bayford, J., Brown, L., Quaye, M., Kinnon, C., Ancliff, P., Webb, D. K., Schmidt, M., von Kalle, C., Gaspar, H. B. and Thrasher, A. J. (2008), “Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients”, Journal of Clinical Investigation, Vol. 118 No. 9, pp. 3143-50.
Kohn, D. B., Booth, C., Kang, E. M., Pai, S., Shaw, K. L., Santilli, G., Armant, M., Buckland, K. F., Choi, U., Ravin, S. S. D., Dorsey, M. J., Kuo, C. Y., Leon-Rico, D., Rivat, C., Izotova, N., Gilmour, K., Snell, K., Dip, J. X., Darwish, J., Morris, E. C., Terrazas, D., Wang, L. D., Bauser, C. A., Paprotka, T., Kuhns, D. B., Gregg, J., Raymond, H. E., Everett, J. K., Honnet, G., Biasco, L., Newburger, P. E., Bushman, F. D., Grez, M., Gaspar, H. B., Williams, D. A., Malech, H. L., Galy, A. and Thrasher, A. J. (2020), “Lentiviral gene therapy for X-linked chronic granulomatous disease”, Vol. 26 No. 2, pp. 200-6.
Kohn, D. B., Chen, Y. Y. and Spencer, M. J. (2023), “Successes and challenges in clinical gene therapy”, Gene Therapy, Vol. 30, pp. 738-46.
Kohn, D. B., Pai, S. and Sadelain, M. (2013), “Gene therapy through autologous transplantation of gene-modified hematopoietic stem cells”, Biology of Blood and Marrow Transplantation, Vol. 19 No. 1, pp. S64-9.
Kohn, D. B., Sevilla, J., Rao, G., Chitty-Lopez, M., Almarza, D., Terrzas, D., Zubicaray, J., Gonzalez-Vicent, M., Chetty, K., O’Toole, G., Xu-Bayford, J., Nicoletti, E., Fernandes, A., Kuo, C., de Oliveira, S., Moore, T. B., Choi, G., Zeini, M., Mesa-Nunez, C., Thrasher, A. J., Bueren, J. and Schwartz, J. D. (2022), “Interim results from an ongoing phase 1/2 study of lentiviral-mediated ex-vivo gene therapy for pediatric patients with severe leukocyte adhesion deficiency-I (LAD-1)”, Molecules Therapy, Vol. 30, pp. 550.
Magnani, A., Semeraro, M., Adam, F., Booth, C., Dupré, L., Morris, E. C., Gabrion, A., Roudaut, C., Borgel, D., Toubert, A., Clave, E., Abdo, C., Gorochov, G., Petermann, R., Guiot, M., Miyara, M., Moshous, D., Magrin, E., Denis, A., Suarez, F., Lagresle, C., Roche, A. M., Everett, J., Trinquand, A., Guisset, M., Bayford, J. X., Hacein-Bey-Abina, S., Kauskot, A., Elfeky, R., Rivat, C., Abbas, S., Gaspar, H. B., Macintyre, E., Picard, C., Bushman, F. D., Galy, A., Fischer, A., Six, E., Thrasher, A. J. and Cavazzana, M. (2022), “Long-term safety and efficacy of lentiviral hematopoietic stem/progenitor cell gene therapy for Wiskott-Aldrich syndrome”, Nature Medicine, Vol. 28 No. 1, pp. 71-80.
Pai, S., Logan, B. R., Griffith, L. M., Buckley, R. H., Parrott, R. E., Dvorak, C. C., Kapoor, N., Hanson, I. C., Filipovich, A. H., Jyonouchi, S., Sullivan, K. E., Small, T. N., Burroughs, L., Skoda-Smith, S., Haight, A. E., Grizzle, A., Pulsipher, M. A., Chan, K. W., Fuleihan, R. L., Haddad, E., Loechelt, B., Aquino, V. M., Gillio, A., Davis, J., Knutsen, A., Smith, A. R., Moore, T. B., Schroeder, M. L., Goldman, F. D., Connelly, J. A., Porteus, M. H., Xiang, Q., Shearer, W. T., Fleisher, T. A., Kohn, D. B., Puck, J. M., Notarangelo, L. D., Cowan, M. J. and O’Reilly, R. J. (2014), “Transplantation outcomes for severe combined immunodeficiency, 2000-2009”, The New England, Journal of Medicine, Vol. 371 No. 5, pp. 434-46.
Staal, F. J. T., Aiuti, A. and Cavazzana, M. (2019), “Autologous Stem-Cell-Based Gene Therapy for Inherited Disorders: State of the Art and Perspectives”, Frontiers in Pediatrics, Vol. 7.
Copyright (c) 2024 Journal of Stem Cell Research and Tissue Engineering
This work is licensed under a Creative Commons Attribution 4.0 International License.
1. As an author you (or your employer or institution) may do the following:
- make copies (print or electronic) of the article for your own personal use, including for your own classroom teaching use;
- make copies and distribute such copies (including through e-mail) of the article to research colleagues, for the personal use by such colleagues (but not commercially or systematically, e.g. via an e-mail list or list server);
- present the article at a meeting or conference and to distribute copies of the article to the delegates attending such meeting;
- for your employer, if the article is a ‘work for hire', made within the scope of your employment, your employer may use all or part of the information in the article for other intra-company use (e.g. training);
- retain patent and trademark rights and rights to any process, procedure, or article of manufacture described in the article;
- include the article in full or in part in a thesis or dissertation (provided that this is not to be published commercially);
- use the article or any part thereof in a printed compilation of your works, such as collected writings or lecture notes (subsequent to publication of the article in the journal); and prepare other derivative works, to extend the article into book-length form, or to otherwise re-use portions or excerpts in other works, with full acknowledgement of its original publication in the journal;
- may reproduce or authorize others to reproduce the article, material extracted from the article, or derivative works for the author's personal use or for company use, provided that the source and the copyright notice are indicated, the copies are not used in any way that implies JSCRTE endorsement of a product or service of any employer, and the copies themselves are not offered for sale.
All copies, print or electronic, or other use of the paper or article must include the appropriate bibliographic citation for the article's publication in the journal.
2. Requests from third parties
Although authors are permitted to re-use all or portions of the article in other works, this does not include granting third-party requests for reprinting, republishing, or other types of re-use. Requests for all uses not included above, including the authorization of third parties to reproduce or otherwise use all or part of the article (including figures and tables), should be referred to JSCRTE by going to our website at http://e-journal.unair.ac.id/index.php/JSCRTE
3. Author Online Use
- Personal Servers. Authors and/or their employers shall have the right to post the accepted version of articles pre-print version of the article, or revised personal version of the final text of the article (to reflect changes made in the peer review and editing process) on their own personal servers or the servers of their institutions or employers without permission from JSCRTE, provided that the posted version includes a prominently displayed JSCRTE copyright notice and, when published, a full citation to the original publication, including a link to the article abstract in the journal homepage. Authors shall not post the final, published versions of their papers;
- Classroom or Internal Training Use. An author is expressly permitted to post any portion of the accepted version of his/her own articles on the author's personal web site or the servers of the author's institution or company in connection with the author's teaching, training, or work responsibilities, provided that the appropriate copyright, credit, and reuse notices appear prominently with the posted material. Examples of permitted uses are lecture materials, course packs, e-reserves, conference presentations, or in-house training courses;
- Electronic Preprints. Before submitting an article to an JSCRTE, authors frequently post their manuscripts to their own web site, their employer's site, or to another server that invites constructive comment from colleagues. Upon submission of an article to JSCRTE, an author is required to transfer copyright in the article to JSCRTE, and the author must update any previously posted version of the article with a prominently displayed JSCRTE copyright notice. Upon publication of an article by the JSCRTE, the author must replace any previously posted electronic versions of the article with either (1) the full citation to the work with a Digital Object Identifier (DOI) or link to the article abstract in JSCRTE homepage, or (2) the accepted version only (not the final, published version), including the JSCRTE copyright notice and full citation, with a link to the final, published article in journal homepage.
4. Articles in Press (AiP) service
JSCRTE may choose to publish an abstract or portions of the paper before we publish it in the journal. Please contact our Production department immediately if you do not want us to make any such prior publication for any reason, including disclosure of a patentable invention.
5. Author/Employer Rights
If you are employed and prepared the article on a subject within the scope of your employment, the copyright in the article belongs to your employer as a work-for-hire. In that case, JSCRTE assumes that when you sign this Form, you are authorized to do so by your employer and that your employer has consented to the transfer of copyright, to the representation and warranty of publication rights, and to all other terms and conditions of this Form. If such authorization and consent has not been given to you, an authorized representative of your employer should sign this Form as the Author.
6. JSCRTE Copyright Ownership
It is the formal policy of JSCRTE to own the copyrights to all copyrightable material in its technical publications and to the individual contributions contained therein, in order to protect the interests of the JSCRTE, its authors and their employers, and, at the same time, to facilitate the appropriate re-use of this material by others. JSCRTE distributes its technical publications throughout the world and does so by various means such as hard copy, microfiche, microfilm, and electronic media. It also abstracts and may translate its publications, and articles contained therein, for inclusion in various compendiums, collective works, databases and similar publications
Every accepted manuscript should be accompanied by "Copyright Transfer Agreement" prior to the article publication.
